Study on Pembrolizumab with or without Chemotherapy for Stage IV Non-small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with Stage IV non-small cell lung cancer (NSCLC), either squamous or non-squamous type.
• Not eligible for approved targeted therapy if they have non-squamous NSCLC.
• Able to provide a tumor tissue sample from a previous biopsy or a new biopsy taken within 90 days before starting treatment.
• Have not received any prior systemic treatment for their metastatic NSCLC.
• Able to complete all required screening procedures within the specified time frames.

Exclusion Criteria

• Diagnosed with small cell lung cancer.
• Have an immune system deficiency or are taking high doses of steroids or other immune-suppressing medications.
• Have another active cancer that is progressing or required treatment in the past 2 years.
• Have cancer that has spread to the brain or spinal cord.
• Have an active autoimmune disease needing treatment in the past 2 years.
• Have a history of lung inflammation requiring steroids or current lung inflammation.
• Have an active infection needing treatment.
• Have significant heart disease, such as recent heart attack or severe heart failure.
• Have uncontrolled HIV, Hepatitis B, or Hepatitis C infections.
• Have had major surgery within 3 weeks before starting the study treatment.
• Need other cancer treatments while on the study.
• Have digestive or liver conditions affecting medication absorption.
• Have moderate nerve damage.
• Have received certain cancer treatments or radiation therapy recently.
• Have had severe allergic reactions to similar treatments.
• Have had a tissue or organ transplant.